JP2015533163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533163A5 JP2015533163A5 JP2015536853A JP2015536853A JP2015533163A5 JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5 JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015536853 A JP2015536853 A JP 2015536853A JP 2015533163 A5 JP2015533163 A5 JP 2015533163A5
- Authority
- JP
- Japan
- Prior art keywords
- multiple sclerosis
- laquinimod
- relapsing
- presenting
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 1
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 1
- 229960004577 laquinimod Drugs 0.000 claims 1
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713256P | 2012-10-12 | 2012-10-12 | |
| US61/713,256 | 2012-10-12 | ||
| PCT/US2013/064061 WO2014058979A2 (en) | 2012-10-12 | 2013-10-09 | Laquinimod for reducing thalamic damage in multiple sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015533163A JP2015533163A (ja) | 2015-11-19 |
| JP2015533163A5 true JP2015533163A5 (OSRAM) | 2016-11-24 |
Family
ID=50475887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015536853A Pending JP2015533163A (ja) | 2012-10-12 | 2013-10-09 | 多発性硬化症における視床損傷を低減するためのラキニモド |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20140107154A1 (OSRAM) |
| EP (1) | EP2961406A4 (OSRAM) |
| JP (1) | JP2015533163A (OSRAM) |
| KR (1) | KR20150080509A (OSRAM) |
| CN (1) | CN105263325A (OSRAM) |
| AR (1) | AR092993A1 (OSRAM) |
| AU (2) | AU2013329348A1 (OSRAM) |
| BR (1) | BR112015007782A2 (OSRAM) |
| CA (1) | CA2884272A1 (OSRAM) |
| CL (2) | CL2015000732A1 (OSRAM) |
| EA (1) | EA201590726A1 (OSRAM) |
| HK (1) | HK1218865A1 (OSRAM) |
| IL (1) | IL237745A0 (OSRAM) |
| MX (1) | MX2015004564A (OSRAM) |
| PE (1) | PE20151435A1 (OSRAM) |
| SG (1) | SG11201501874TA (OSRAM) |
| TW (1) | TW201420101A (OSRAM) |
| WO (1) | WO2014058979A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140235670A1 (en) * | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries, Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| HK1225972A1 (zh) * | 2013-12-20 | 2017-09-22 | Teva Pharmaceutical Industries Ltd. | 利用拉喹莫德来延缓亨廷顿氏病的进展 |
| SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
| WO2017048457A1 (en) * | 2015-09-18 | 2017-03-23 | Teva Pharmaceuticals Industries Ltd. | Combination of laquinimod and pridopidine to treat multiple sclerosis |
| KR20190064583A (ko) * | 2016-09-13 | 2019-06-10 | 인테크린 테라퓨틱스, 아이엔씨. | Chs-131로 다발성 경화증의 치료 |
| SG11201909046XA (en) | 2017-04-03 | 2019-10-30 | Coherus Biosciences Inc | PPARγ AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
| CN113397757A (zh) * | 2021-06-07 | 2021-09-17 | 温州医科大学 | 用于测试拉喹莫德在治疗缺血性脑卒中的作用的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006076681A2 (en) * | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| CA2657716A1 (en) * | 2006-07-17 | 2008-01-24 | Novartis Ag | Cholanic acid amides |
| TW201438738A (zh) * | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| AU2010282948C1 (en) * | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| US20130035390A1 (en) * | 2010-01-13 | 2013-02-07 | Ramot At Tel-Aviv University Ltd. | Treatment of multiple sclerosis |
| EP2648732A4 (en) * | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| HK1199820A1 (en) * | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-10-09 CN CN201380053184.1A patent/CN105263325A/zh active Pending
- 2013-10-09 US US14/049,411 patent/US20140107154A1/en not_active Abandoned
- 2013-10-09 AU AU2013329348A patent/AU2013329348A1/en not_active Abandoned
- 2013-10-09 EA EA201590726A patent/EA201590726A1/ru unknown
- 2013-10-09 PE PE2015000472A patent/PE20151435A1/es not_active Application Discontinuation
- 2013-10-09 JP JP2015536853A patent/JP2015533163A/ja active Pending
- 2013-10-09 BR BR112015007782A patent/BR112015007782A2/pt active Search and Examination
- 2013-10-09 HK HK16106893.7A patent/HK1218865A1/zh unknown
- 2013-10-09 WO PCT/US2013/064061 patent/WO2014058979A2/en not_active Ceased
- 2013-10-09 EP EP13895446.6A patent/EP2961406A4/en not_active Withdrawn
- 2013-10-09 SG SG11201501874TA patent/SG11201501874TA/en unknown
- 2013-10-09 CA CA2884272A patent/CA2884272A1/en not_active Abandoned
- 2013-10-09 MX MX2015004564A patent/MX2015004564A/es unknown
- 2013-10-09 KR KR1020157012465A patent/KR20150080509A/ko not_active Withdrawn
- 2013-10-11 AR ARP130103705A patent/AR092993A1/es unknown
- 2013-10-11 TW TW102136847A patent/TW201420101A/zh unknown
-
2015
- 2015-03-15 IL IL237745A patent/IL237745A0/en unknown
- 2015-03-23 CL CL2015000732A patent/CL2015000732A1/es unknown
-
2016
- 2016-06-17 US US15/186,163 patent/US20160296511A1/en not_active Abandoned
- 2016-11-11 CL CL2016002873A patent/CL2016002873A1/es unknown
-
2017
- 2017-06-08 AU AU2017203896A patent/AU2017203896A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533163A5 (OSRAM) | ||
| HRP20210819T1 (hr) | Fenfluramin za uporabu u liječenju dravet sindroma | |
| JP2013014622A5 (OSRAM) | ||
| JP2016518337A5 (OSRAM) | ||
| JP2013520167A5 (OSRAM) | ||
| MX2015004565A (es) | Metodo y dispositivo para conmutacion de camaras. | |
| JP2014507446A5 (OSRAM) | ||
| JP2015525757A5 (OSRAM) | ||
| CL2013001602A1 (es) | Metodo para reducir o inhibir la progresion del nivel de fatiga en pacientes con esclerosis multiple y para proporcionarles neuroproteccion que comprende administrar oralmente laquinimod o una sal del mismo; laquinimod para reducir el nivel de fatiga, mejorar el estado funcional y entregar neuroproteccion en esclerosis multiple. | |
| BR112014010177A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença | |
| CL2014000209A1 (es) | Metodo para tratar esclerosis multiple que comprende el uso de laquinimod y acetato de glatiramero y kit que comprende composiciones farmaceuticas conteniendo a ambos compuestos independientemente. | |
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| JP2015528502A5 (OSRAM) | ||
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| JP2017514871A5 (OSRAM) | ||
| JP2015534562A5 (OSRAM) | ||
| WO2014058979A8 (en) | Laquinimod for reducing thalamic damage in multiple sclerosis | |
| WO2013003669A3 (en) | Compositions, methods of use, and methods of treatment | |
| JP2016500312A5 (OSRAM) | ||
| BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
| MX374944B (es) | Derivado de piranocromenil fenol, y composición farmacéutica para tratar un síndrome metabólico o enfermedad inflamatoria. | |
| JP2014526468A5 (OSRAM) | ||
| WO2014153495A9 (en) | Novel stat3 inhibitors | |
| HUE041883T2 (hu) | Samidorphan (ALKS 33) és buprenorfin kombináció, depressziós zavarok kezelésére |